SMSigne Modvig

Signe Modvig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Signe Modvig has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cerebrospinal fluid chitinase‐3‐like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis

    by M. Møllgaard, M. Degn, F. Sellebjerg, J. L. Frederiksen, S. Modvig

    Background and purpose: The role of chitinases and chitinase‐like proteins in multiple sclerosis (MS) is currently unknown; however, cerebrospinal fluid (CSF) levels of chitinase 3‐like 1 (CHI3L1) predict prognosis in early MS. Whether this applies to other chitinases and chitinase‐like proteins is yet to be established. Our objective was to investigate the potential of chitinase 3‐like 2 (CHI3L2) and chitotriosidase as prognostic biomarkers in optic neuritis (ON) as the first demyelinating episode and to evaluate the ability of CHI3L2 to predict long‐term MS risk and disability.Methods: In a prospective cohort of 73 patients with ON as a first demyelinating episode and 26 age‐matched healthy controls levels of CHI3L2 and chitotriosidase in CSF were explored by enzyme‐linked immunosorbent assay. Associations with magnetic resonance imaging white matter lesions, CSF oligoclonal bands, immunoglobulin G index and leukocyte count were investigated. Long‐term MS risk and disability (Expanded Disability Status Scale, Multiple Sclerosis Functional Composite components) were examined in a retrospective cohort of 78 patients with ON as the first demyelinating episode (mean follow‐up 14 years). The predictive ability of CHI3L2 was compared with CHI3L1.Results: Cerebrospinal fluid levels of CHI3L2 and chitotriosidase were significantly elevated in patients with ON and were associated with MS risk measures. CHI3L2 levels predicted MS development after ON (hazard ratio 1.95, P = 0.00039, Cox regression) and cognitive impairment by the Paced Auditory Serial Addition Test (P = 0.0357, linear regression) at follow‐up. In a multivariate analysis of MS risk, CHI3L2 performed better than CHI3L1.Conclusions: CHI3L2 and chitotriosidase are promising biomarkers in patients with a first demyelinating episode. Our findings thus support a role for these proteins as biomarkers in early MS.


  • Increased prevalence of LTi cells in CSF of patients with early MS

    by Matilda Degn, Signe Modvig, Beatrice D. Andersen, Charlotte M. Bonefeld, Jette L. Frederiksen, Carsten Geisler, Marina Rode Von Essen

    • 21 May 2012
      • Vol. 174  (21) , 1452-6

    [Autoimmune synaptic encephalitis is a disease entity on the rise].

    by Signe Modvig, Christina Engel Høi-Hansen, Peter Uldall, Finn Somnier

    The term autoimmune synaptic encephalitis (ASE) comprises encephalitides associated with autoantibodies against structures of the neuronal synapse. We review four types of ASE (anti-N-methyl-D-aspartate receptor encephalitis, anti-α-amine-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor encephalitis, anti-gamma-aminobutyric acid receptor 1 encephalitis and anti-leucine-rich glioma-inactivated 1 encephalitis) including their epidemiology, clinical characteristics and treatment.

    • 21 May 2012
      • Vol. 174  (21) , 1456-8

    [Autoimmune synaptic encephalitis].

    by Signe Modvig, Christina Engel Høi-Hansen, Peter Uldall, Finn Somnier

    Autoimmune synaptic encephalitis (ASE) is a recently recognized disease entity. The early and correct diagnosis of ASE is of importance, since the prognosis depends on the early onset of treatment. We present two Danish case reports of ASE: a 15-year-old boy presenting with a severe course of N-methyl-D-aspartate-encephalitis including persistent cognitive deficits, and a 59-year-old woman with coeliac disease presenting with leucine-rich glioma inactivated 1-encephalitis including dyskinesia, epilepsy, psychiatric features and vocal tics.